Diagnostic value of MRS-quantified brain tissue lactate level in identifying children with mitochondrial disorders by Roelineke J. Lunsing et al.
MAGNETIC RESONANCE
Diagnostic value of MRS-quantified brain tissue lactate level
in identifying children with mitochondrial disorders
Roelineke J. Lunsing1 & Kim Strating1 & Tom J. de Koning2 & Paul E. Sijens3
Received: 5 April 2016 /Revised: 12 May 2016 /Accepted: 25 May 2016 /Published online: 7 June 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Objectives Magnetic resonance spectroscopy (MRS) of chil-
dren with or without neurometabolic disease is used for the
first time for quantitative assessment of brain tissue lactate
signals, to elaborate on previous suggestions of MRS-
detected lactate as a marker of mitochondrial disease.
Methods MultivoxelMRS of a transverse plane of brain tissue
cranial to the ventricles was performed in 88 children
suspected of having neurometabolic disease, divided into ‘def-
inite’ (n=17, ≥1 major criteria), ‘probable’ (n=10, ≥2 minor
criteria), ‘possible’ (n=17, 1 minor criterion) and ‘unlikely’
mitochondrial disease (n=44, none of the criteria). Lactate
levels, expressed in standardized arbitrary units or relative to
creatine, were derived from summed signals from all voxels.
Ten ‘unlikely’ children with a normal neurological exam
served as the MRS reference subgroup. For 61 of 88 children,
CSF lactate values were obtained.
Results MRS lactate level (>12 arbitrary units) and the lactate-
to-creatine ratio (L/Cr >0.22) differed significantly between the
definite and the unlikely group (p=0.015 and p=0.001, respec-
tively). MRS L/Cr also differentiated between the probable and
the MRS reference subgroup (p=0.03). No significant group
differences were found for CSF lactate.
Conclusion MRS-quantified brain tissue lactate levels can
serve as diagnostic marker for identifying mitochondrial dis-
ease in children.
Key points
• MRS-detected brain tissue lactate levels can be quantified.
• MRS lactate and lactate/Cr are increased in children with
mitochondrial disease.
• CSF lactate is less suitable as marker of mitochondrial
disease.
Keywords Cerebrospinal fluid . Lactate . Magnetic
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Introduction
Mitochondrial disorders represent a clinically, biochemically,
and genetically heterogeneous group of diseases associated
with dysfunction of the oxidative phosphorylation system
(OXPHOS) [1]. Although most individual OXPHOS disorders
are rare, epidemiological evidence suggests that the minimum
birth prevalence is 1 in 7634 [2]. Curative treatment for the
conditions remains elusive, and so does symptomatic treatment
in most cases. Nevertheless, correct diagnosis of an OXPHOS
disorder is important for prognosis, genetic counseling, and
supportive management of associated impairments [3].
In mitochondrial disorders the process of adenosine triphos-
phate (ATP) production is disrupted. Low ATP results in an
upregulation of glycolysis, leading to an overproduction of py-
ruvate, and this excess pyruvate is either transaminated to ala-
nine or reduced to form lactate [4]. Venous lactate acidosis/lactic
acidosis or elevated lactate is generally considered as a clinically
relevant indicator for mitochondrial disease, but unfortunately
can be falsely positive or negative. Cerebrospinal fluid lactate
(CSF) may be elevated, even in the presence of normal venous
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lactate values [5, 6]. CSF lactate values may therefore be a more
reliable diagnostic marker for a mitochondrial disorder than ve-
nous lactate in patients with neurological symptoms. Magnetic
resonance spectroscopy (MRS) is a non-invasive functional
brain imaging method that is capable of detecting biochemical
metabolites in vivo. N-acetyl-aspartate (NAA) reduction and
lactate accumulation in both the cerebral white and gray matter
are the most prominent MRS signal abnormalities observed in
mitochondrial disorders [7–14]. Lactate level elevation in the
brain tissue of patients with mitochondrial disease, is even ob-
served in the absence of systemic lactic acidosis [15].
The present study evaluated whether or not MRS brain tis-
sue lactate values and CSF lactate values are good diagnostic
markers for identifying children with mitochondrial diseases in
a group of children suspected of having a neurometabolic dis-
ease. In our experience with multivoxel proton MRS [16], the
summing of the MRS signals from multiple gray and white
matter brain tissue voxels improves the detectability of metab-
olites owing to gains in the signal-to-noise ratio (SNR), which
is proportional to total voxel volume provided that B0 and B1
homogeneity are such that line broadening is negligible
[17–19]. A new aspect in this MRS study of brain lactate levels
is that, compared with studies performed elsewhere, the signals
in larger volumes of brain tissue are summed, allowing for
better SNRs and thus quantitative assessment of lactate in chil-
dren with or without neurometabolic disease.
Materials and methods
Subjects
This retrospective study was conducted at the University
Medical Center Groningen, in accordance with the
Declaration of Helsinki (Seoul, 2008). The requirement of in-
formed consent was waived by the medical-ethical committee
of the University Medical Center Groningen, since the study
was retrospective and involved post-processing of clinical data.
From our medical records, we identified 96 patients under the
age of 18 years in whom magnetic resonance imaging (MRI)
including MRS was performed. These patients underwent MRI/
MRS and a lumbar puncture, because of clinical suspicion of a
neurometabolic disorder including mitochondrial disease, be-
tween January 2003 and July 2013. CSF lactate values and other
information were obtained from patient files. Patients with dis-
orders that may cause a lactate rise, like subarachnoid haemor-
rhage,meningitis, encephalitis, and ischemia, were excluded [20,
21]. Patients with seizures, frequent in mitochondrial disease
(22), were included. Eight patients were excluded in the process
of calculating the MRS data because of: (1) adding of the voxel
signals was not possible (n=2); (2) voxel measurements were
not made in a standard area of the brain (n=2) (data were not
comparable, because different areas of the brain have different
metabolite concentrations); (3) MRS data were lost (n=2); (4)
too much fluid in the volume of interest prohibited the selection
of voxels mainly containing brain tissue (n=1); and (5) poor
spectra (n=1) (poor resolution between metabolite peaks, prob-
ably because of movement of the patient during the MRS scan).
In total, 88 patients were included.Median age at first MRS scan
was 3.9 years (range 0 months to 15.2 years); there were four
patients that underwent their first MRS scan at neonatal age
(<2 months), 28 infantile (3 months to 2 years), 37 in early
childhood (2–6 years) and 19 in late childhood (>6 years).
We constructed a scoring system to determine the likelihood
of mitochondrial disease (Table 1). The mitochondrial disease
scoring system was adapted from existing scoring systems [23]
and based on several criteria including clinical features, MRI
abnormalities associated with mitochondrial disease, muscle
biopsy results (ATP production speed and enzymatic complex
deficiencies), and genetic abnormalities associated with mito-
chondrial disease. We divided the subjects into four categories:
Table 1 Mitochondrial disease scoring
I. Minor diagnostic criteria
a) Abnormal muscle biopsy with lower mitochondrial energy production
capacity
ATP production speed< 42.1 nmol/h.mUCS
b) MRI abnormalities associated with mitochondrial disease
Abnormality in the basal ganglia, the thalamus, mesencephalon and/or
brainstem, and/or atrophy (for instance, abnormalities associated with
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like
episodes (MELAS) or Leigh syndrome)
c) Strong clinical suspicion of mitochondrial disease based on the
experience of a team of child neurologists and metabolic pediatricians
Symptoms associated with mitochondrial disease: therapy resistant status
epilepticus, ophthalmoplegia, ptosis, retinopathy, hearing impairment,
and movement disorders such as ataxia (without a known cause),
pyramidal and/or extra pyramidal signs, and/or familial mitochondrial
disease
II. Major diagnostic criteria
d) DNA mutations associated with mitochondrial diseases
Mitochondrial DNA mutations, core-bound DNA deletions
(mitochondrial deletion syndrome), POLG1* gene mutations and
OPA1** gene mutations
e) Enzymatic complex deficiency
Muscle biopsy
1. Mitochondrial disease unlikely: None of the minor or major criteria are
present.
2. Possible mitochondrial disease: One of the minor criterions is present.
3. Probable mitochondrial disease: Two or more minor criteria are
present.
4. Definitive mitochondrial disease: One or more major criterion is
present.
* POLG (alias, POLG1 or POLGa) is the gene that codes for the catalytic
subunit of the mitochondrial DNA polymerase, called DNA polymerase
gamma
**OPA1 is the gene that codes for the protein dynamin-like 120 kDa
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1 ‘Mitochondrial disease unlikely’, none of the criteria; 2
‘Possible mitochondrial disease’, with one minor criterion i.e.
ATP production rate <42.1 nmol/h.mUCS, compatible MRI
abnormalities, or strong clinical suspicion; 3 ‘Probable mito-
chondrial disease’, ≥2 minor criteria, and 4 ‘Definite mitochon-
drial disease’, ≥1 major criteria, i.e. mitochondrial DNA muta-
tion and/or enzymatic complex deficiency in muscle biopsy.
From group 1 (‘mitochondrial disease unlikely’) we selected
10 children with a normal neurological exam in order to have
the closest possible to a true control group (current guidelines
do not allow for healthy infants serving as controls). This group
is further referred to as the MRS reference subgroup. Using the
mitochondrial disease scoring system 17 patients (19.3 %)
scored a 4 ‘definite mitochondrial disease’, 10 patients
(11.4 %) scored a 3 ‘probable mitochondrial disease’, 17 pa-
tients (19.3 %) scored a 2 ‘possible mitochondrial disease’, and
44 patients (50 %) scored a 1 ‘Mitochondrial disease unlikely’.
Patient characteristics are listed in Table 2.
Methods
MRI/MR spectroscopy Pediatric brain MRI was performed
using Siemens 1.5 T MR Scanners (subsequently the SP,
Sonata, Avanto, and Aera product line), in a minority of cases
under general anesthesia following institutional guidelines.
The routine protocol included sagittal T1 weighted, axial
T2-weighted, and axial fluid attenuated inversion recovery
sequences that were used for multi-section spectroscopic im-
aging localization (Fig. 1). Two certified specialists, i.e. a pe-
diatric neuroradiologist and a pediatric neurologist, that were
blinded to the classification results interpreted the radiological
studies in consensus. Imaging evaluation included: (1) ‘nor-
mal’; (2) ‘abnormality in the basal ganglia’; (3) ‘abnormality
in the mesencephalon and/or brainstem’; (4) ‘atrophy’; (5)
‘abnormality in the thalamus’, and (6) ‘a combination of two
or more of the possible abnormalities’ [2–5]. MRS studies
were limited to our standard pediatric protocol of point-
resolved spectroscopy (PRESS) combined with 2D chemical
shift imaging (repetition time 1500 ms, echo time 135 ms) to
obtain a transverse plane of typically 36 or 49 voxels of 1x1x2
cm3 each, located cranial to the ventricles [17]. Focal abnor-
malities, as may be present in different parts of the brain such
as the basal ganglia, were therefore not featured. With this
MRS method and using the manufacturer’s Syngo post-
processing software, observer-independent automated metab-
olite peak areas are obtained for choline (Cho), creatine (Cr),
N-acetylaspartate (NAA), inositol (Ins), and lactate (L) for an
array of voxels containing gray and white matter [17]. In order
to get adequate SNRs for the lactate peaks, MRS peak areas
were summed for the entire region of interest of 36-49 voxels
(54-73.5 cm3) and quantified. The results in arbitrary units,
a.u., were standardized by referring to the unsuppressed water
signal and also assessed relative to creatine (L/Cr).
Reference values
Reference values for venous lactate levels and CSF lactate levels
were based on historical age-related values from our own labo-
ratory. Normal venous lactate: 0.5 – 2.2 mmol/l; CSF lactate: 0.9
– 1.9 mmol/l. The reference value for ATP production rate from
pyruvate in muscle biopsy was 42.1 – 81.2 nmol/h.mUCS. The
normal MRS reference ranges for lactate (0 – 12 a.u.) and for the
lactate/creatine (L/Cr) ratio (0 – 0.22) were obtained from our
own MRS data. In the unlikely group, the highest value was 12
(Fig. 2a). Therefore, we defined elevated lactate as>12. For L/Cr
ratio, after correction for three Boutliers^ reflecting the different
metabolite proportions up to 0.8 years after birth23, the highest
value in the unlikely group was 0.22, therefore, we defined ele-
vated L/Cr ratio as >0.22 (Fig. 2b). Blood lactate values (n=88)
and CSF lactate values (n=61) were available from most pa-
tients. Themissing values for blood lactate andCSF lactate reflect
a lack of clinical indication. Venous blood was collected by ve-
nipuncture and CSF was obtained by lumbar puncture under
sterile conditions. For patients from whom more than one blood
or CSF sample was taken, the highest lactate level was taken.
Statistical analyses
Descriptive statistical methods were used to assess fre-
quency distributions and means. Because there was no
Table 2 Patient characteristics
Category N Male/Female Age (yr) Venous lactate CSF lactate MRS lactate MRS L/Cr
(%) (mean) (meana) (meana) (mean; a.u.) (mean)
Unlikely 44 68/32 4.6 (±4.1) 1.5 (±0.9) 1.5 (±0.3) 8.2 (±2.1) 0.17 (±0.04)
Possible 17 47/53 4.0 (±3.4) 2.1 (±1.5) 1.6 (±0.3) 8.9 (±3.6) 0.2 (±0.07)
Probable 10 60/40 2.3 (±1.6) 2.5 (±2.9) 2.3 (±2.4) 10.6 (±10.0) 0.23 (±0.08)
Definite 17 59/41 3.3 (±3.7) 3.7 (±3.0) 2.3 (±2.1) 11.2 (±5.5) 0.28 (±0.2)
N, number; yr, years; CSF, cerebral spinal fluid; MRS, magnetic resonance spectroscopy; L/Cr, lactate/creatine ratio; a.u., arbitrary units; ±, ± standard
deviation of the mean; a Values in mmol/l
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normal distribution of the data, the Mann-Whitney U test
was used. Differences were regarded as statistically signif-
icant when P < 0.05. All statistical tests were performed
using SPSS for Windows version 20 (SPSS Omc,
Chicago, Illinois USA). Although brain lactate levels are
known to be higher in young infants, group analyses were
not split into age categories to prevent arbitrary choices
and small-group statistics.
Results
Of the 88 patients included, 34 were female (38.6 %) and
54 were male (61.4 %). Mean age was 3.9 years (see
Table 2). MRS lactate values > 12 a.u. differentiated sig-
nificantly between the definite group (4/17, 24 %) and the
unlikely group (0/44, 0 %, p = 0.015). No other significant
differences were found between groups (Table 3). MRS L/
Cr ratio values (>0.22) also differentiated significantly
between the definite group (9/17, 53 %) and the unlikely
group (3/44, 7 %, p = 0.001). There was also a significant
difference between the definite group and the MRS refer-
ence subgroup defined as unlikely with a normal neuro-
logical exam (1/10, 10 %, p = 0.04). MRS L/Cr ratio
values (>0.22) differentiated significantly between the
probable group (5/10, 50 %) and the MRS reference sub-
group (1/10, 10 %, p = 0.03). No other significant differ-
ences were found between groups. Note that at age under
0.8 years there were respectively 3/3, 1/2, 2/2 and 3/8
patients with L/Cr > 0.22 in the definite, probable, possi-
ble, and unlikely patient groups, and just two definites
and one probable with lactate > 0.12 (Fig. 2).
Remarkably, no significant differences between groups
were found for the incidence of CSF lactate elevation
(>1.9 mmol/l), including the definite group (see Table 3).
Detailed patient characteristics of the definite mitochondrial
disease group are listed in Appendix 1, and the characteristics
of the unlikely mitochondrial disease group, including the
MRS reference subgroup (the first 10 patients) are listed in
Appendix 2. Venous lactate values were significantly higher in
the definite group (p<0.001) and the possible group (p=0.04)
in comparison with the unlikely group (Table 3).
Discussion
The concentration of Cr in brain tissue is relatively constant
and little affected by age or by the presence of pathology [18].
Conforming to common practice in clinical MRS, we there-
fore used it as an internal reference for calculating metabolite
Fig. 1 1HMR spectroscopy of a representative supraventricular region of
interest (ROI), volume 7 × 7 × 2 cm2 (a, b). The resulting spectral map of
the transverse plain, 36 voxels of 1 × 1 × 2 cm2 each (c). Representative
summed spectrum for the entire ROI of a child from the unlikely group
showing a modest lactate peak (the inverted doublet at 1.33 ppm) (d), and
one of a child from the definite group showing increased lactate (e).
p.p.m., parts per million
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ratios (lactate to creatine, L/Cr), in order to get values that
were potentially the most comparable between different mea-
surements and subsequent software versions. In our own
database of MRS results for the total of 88 children this ap-
proachwas corroborated by respective coefficients of variance
of 23, 20, 53, 29, and 39 for Cho, Cr. Ins, NAA, and lactate
(for resp. mean peak areas of 55, 47, 3, 78, and 9 a.u.).
In our study, elevated MRS lactate and MRS L/Cr ratio
values were found to be more closely associated with mito-
chondrial disease in children than elevated CSF lactate. Our
quantitative evidence that MRS brain tissue lactate can be an
important clue to mitochondrial disease is in line with previous
qualitative MRS studies. Lin et al. [24] evaluated MRS data of
29 generally young patients with suspected mitochondrial dis-
ease. Patients were divided over three groups based on a clas-
sification of clinical and laboratory features and 4/8 patients
with definitive mitochondrial disease (50 %) had detectable
brain lactate levels on MRS [24]. Among 16 patients that had
possible but not proven mitochondrial disease, three patients
(19 %) had increased lactate levels shown by MRS in the Lin
study [24]. In another study, Dinopoulos et al. evaluated 37
children with suspected mitochondrial disease by MRS [25].
Their patients were divided into three groups according to the
modified adult criteria for mitochondrial disease by Bernier
et al. [26]. Of 16 patients in the definite mitochondrial disease
group, 13 patients (81 %) had detectable lactate [25]. In our
definite group (n=17) four patients (24 %) had elevated MRS
lactate values and nine patients (53 %) had elevated MRS L/Cr
ratio values. In our probable group (n = 10) three patients
Table 3 Incidence of elevated MRS lactate, MRS L/Cr ratio, CSF
lactate values and venous lactate values
MRS values Definite Probable Possible Unlikely
(n = 17) (n = 10) (n = 17) (n = 44)
MRS lactate 4 (24 %)a 3 (30 %) 1 (6 %) 0 (0 %)
>12
MRS L/Cr ratio 9 (53 %)b 5 (50 %)c 7 (41 %) 3 (7 %)
>0.22
CSF values Definite Probable Possible Unlikely
(n = 12) (n = 9) (n =15) (n = 25)
CSF lactate 4 (33 %) 2 (22 %) 1(7 %) 2 (8 %)
>1,9 mmol/l
Serum values Definite Probable Possible Unlikely
(n = 17) (n = 10) (n = 17) (n = 44)
Venous lactate 9 (53 %)d 3 (30 %) 6 (35 %)e 10 (23 %)
>2.2 mmol/l
MRS, magnetic resonance spectroscopy; L/Cr, lactate/creatine; CSF, ce-
rebral spinal fluid. Significant differences between groups: a definite
vs.unlikely, p = 0.015, b definite vs. unlikely, p = 0.001,, c probable vs.
unlikely, p = 0.03, d definite vs. unlikely, p < 0.001, fe possible vs. unlike-



























































Fig. 2 Scatter plot of the MRS lactate values (a) and percent L/Cr ratios (b) in the definite (Δ; n = 17), probable (□; n = 10), possible (◊; n = 17) and
unlikely mitochondrial disease group (○,●; n = 44), and in a subgroup of 10 Bunlikely^ patients with a normal neurological exam (●)
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(30 %) had elevated MRS lactate values and five patients
(50 %) had elevated MRS L/Cr ratio values. So, our MRS
lactate values were less often elevated in the definite group
(24 %) compared to the above-mentioned 50 % in the study
of Lin et al. [24] and 81 % of Dinopoulos et al [25]. This
difference may be coincidental, reflecting the small group sizes,
or may be explained by the differences in group selection and
MRS acquisition and analysis methods. Lin et al. [24] estimated
Bthe presence or absence^ of lactate in 8-cm3 volumes of inter-
est, and Dinopoulos et al. [25] used a similar methodology. In
contrast, in our study all spectra yielded lactate peak areas,
owing to our practice of summing the spectra from the entire
supraventricular region of interest measured (54-73.5 cm3). As
a consequence, their data are more sensitive than the quantita-
tive method we used. However, in the literature it is often seen
that with the application of automated quantitative methods the
results of previous, more subjective evaluations cannot be
reproduced fully. An example is the overestimation of white
matter lesion burden in diabetes, as performed by subjective
raters rather than automated lesion segmentation [27].
Furthermore, our frequency of elevated L/Cr ratio values in
the definite group is similar to the incidence of MRS detectable
lactate according to Lin et al. It thus appears from our data that
in quantitative analysis, the MRS L/Cr ratio value is a better
marker for a mitochondrial disorder than MRS lactate alone. In
addition, Chi et al. [28] assessed lactate peaks on MRS in 14
children with mitochondrial disease. Among these patients,
seven patients were diagnosed with Leigh syndrome, four with
MELAS, one with Pearson syndrome, one with chronic pro-
gressive external ophthalmoplegia (PEO), and one with deaf-
ness dystonia syndrome. Twelve of the 14 patients (86 %) ex-
hibited lactate peaks on the initial single-voxel proton MRS,
and all of them showed abnormal MRI findings. They conclud-
ed that lactate acquisition on MRS supports a diagnosis of a
mitochondrial disease, especially in children with abnormal
signal changes on the brainMRI or a normal blood lactate level.
In our study only two children were diagnosed with clinically
recognizable phenotypes of mitochondrial disease (see
Appendix 1). These two children (one with Leigh syndrome
and one with Alstrom syndrome) both had elevated MRS lac-
tate and elevated MRS L/Cr ratios. Although the number is
very small, it seems that MRS lactate elevation is more fre-
quently seen in patients with recognizable phenotypes of mito-
chondrial disease. Our study adds that if the phenotype of a
mitochondrial disease is less recognizable, MRS brain tissue
lactate and L/Cr ratios can be of diagnostic value too. Noted
here is that according to a recent investigation of 21 patients
suspected of mitochondrial disorder, MRS lactate can be ob-
served in large single voxels centred on the lateral ventricles, in
levels that correlate with lactate CSF concentrations [29].
Further, it can be relevant to localize the MRS in the cerebel-
lum, especially if cerebellar ataxia is the clinical symptom [30].
In summary, previous studies [24, 25, 28, 30, 31] used the
presence of lactate peaks to define elevatedMRS lactate values.
We calculated exact brain tissue MRS lactate values and MRS
L/Cr ratios. This makes it difficult to compare previous results
with our study. Still, the previous studies showed similar find-
ings to ours, that MRS lactate value can be a diagnostic marker
for the diagnosis of mitochondrial disease in children. Our
study adds that in quantitative MRS evaluation, L/Cr ratio
values are preferable to lactate values expressed in a.u., even
when standardized to the unsuppressed water signal.
In our study no significant differences were found between
the mitochondrial disease groups and the unlikely group for
CSF lactate values. This contrasts with the results of Magner
et al [22]. They found that 83 % of the children with mito-
chondrial disorders had increased CSF lactate levels. This lack
of support for our data by previous findings may be explained
by selection bias or the incompleteness of our data. Because of
our retrospective study design, not all patients that underwent
MRS studies also underwent lumbar punctions. With respect
to our results we think that elevated MRS-measured brain
tissue lactate, and even more so MRS L/Cr, are better predic-
tors for mitochondrial disease than laboratory-measured CSF
lactate.
Looking at the venous lactate, we found that of the 17
children in the definite mitochondrial disease group, 53 %
(nine patients) had elevated venous lactate values (Table 2).
In the combined possible, probable, and definite mitochondri-
al disease groups (n=44), only 41 % (18 patients) had elevat-
ed venous lactate values. These findings are supported by the
work of Munnich et al. [5], who examined 1000 children who
had been referred for investigation of their mitochondrial dis-
orders. They found an elevated venous lactate value in only
30 % of the 234 patients. Given the large size of that study,
their result is likely to be representative of the prevalence of
lactic acidosis in children with mitochondrial diseases, and
indicates that even up to 70 % of children with mitochondrial
diseases can have a normal venous lactate value [5]. Also,
three children in our study showed elevated MRS L/Cr values
without elevated venous lactate. This suggests that MRS tis-
sue lactate may be an even better diagnostic marker for mito-
chondrial disease in children than venous lactate, and needs
further study. Given the many confounders that can give rise
to elevated venous lactate, venipunctures often need to be
repeated to gain certainty as to whether it supports the pres-
ence of a mitochondrial disease.
Limitations in this study include that not all patients
underwent a lumbar puncture to determine CSF lactate
values. Another limitation is that patients and not controls
were used as an unlikely group, but this was for obvious
ethical reasons. A third limitation is that the study design
is retrospective. However, because of the low incidence of
mitochondrial disease it would take years to include
enough patients in a prospective study design. A fourth
limitation is that, because of the retrospective design, data
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for patient-related factors were obtained from patient files.
This could lead to incomplete data. Other limitations re-
late to age variation and progression of disease when
MRS scans were obtained. In order to produce a reliable
result from data obtained with different MRI systems and
software, we calculated the L/Cr ratio, also to reduce the
influence of age-related metabolite level changes. In view
of uncertainties about possible changes in the T1- and T2-
relaxation times of the various metabolites with aging and
disease, in this paper we did not attempt to convert the
lactate levels and ratios into metabolite concentrations.
Our study also has strengths. As far as we are aware no
other study of this size has defined a reference range for MRS
brain tissue lactate and MRS L/Cr ratio. Another strength is
our presentation of exact MRS lactate values and MRS L/Cr
ratio values obtained by an automated method employing
curve fitting.
We do hope that our study may be of help to colleagues in
their diagnostic decisions as to whether or not more invasive,
time-consuming, and/or expensive diagnostic procedures such
as muscle biopsy and genetic analysis are necessary.
Hopefully, these invasive diagnostic procedures can be re-
placed by next-generation MRI sequences in the near future,
through research protocols if not routine diagnostics.
Conclusion
What was previously suggested in qualitative MRS studies
based on the subjective assessment of the presence or absence
of lactate signals, has now been confirmed in automated MRS
quantification of brain tissue lactate: lactate and L/Cr can serve
as diagnostic markers for identifying mitochondrial disease in
children, or at least provide supplementary information that
enhances multimodality-based diagnosis. Elevated CSF lactate
appears to be a less sensitive indicator of mitochondrial disease
in children.
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Appendix 1
Table 4 Definite mitochondrial disease group characteristics



















(n = 7) (n = 12) (n = 8)
1. 0.3 Male Leigh syndrome complex
I deficiency
- 0.4 8.5 ND 2 ND 28 90
2. 0.1 Male MD complex II & III deficiency - - 1.6 1.6 3 11.6 8 24
3. 1.7 Female Alström syndrome complex
I & II deficiency
ALMS 1 gene mutation - 2.0 ND 0 ND 14 27
4. 1.2 Male MD POLG 1 gene mutation
c.1550G > T
3.0 1.5 1.6 0 16.5 10 21
5. 1.2 Female MD complex II & III deficiency - - 1.8 1.4 0 20.8 9 28
6. 5.2 Male MD POLG 1 gene mutation - 3.6 1.8 0 29.3 9 18
7. 1.3 Male MD complex I & II deficiency - - 3.5 1.2 4 - 8 18
8. 0.2 Male MD complex I & deficiency - 0.3 10.5 ND 0 9.7 18 64
9. 1.4 Female MD complex II deficiency - - 1.7 1.4 1 ND 10 19
10. 4.4 Female Alpers disease POLG 1 gene mutation 8.2 1.9 3.0 5 ND 11 22
11 0.8 Male MD complex I, II, III & IV deficiency - - 3.0 1.6 0 14.1 5 11
12 10.8 Male MD complex II & III deficiency - - 2.4 2.0 0 ND 9 17
13 2.1 Female MD complex I deficiency POLG 1 gene mutation 2.9 10 8.8 4 20.4 10 24
14 12.6 Male MD complex IV deficiency - 14.2 1.3 1.5 0 ND 9 20
15 3.3 Male MD complex I deficiency - 5.7 2.5 2.0 0 14.1 9 23
16 2.1 Female MD complex I deficiency - - 5.2 ND 5 ND 17 29
17 6.6 Female MD complex I, II, III & PDHC
deficiency
- - 1.6 ND 4 ND 7 16
a age at first MRS scan; b MRS lactate/creatine ratio; MD mitochondrial disease; ND not determined; MRI abnormality score: 0, ‘Normal’ (no
abnormalities); 1, ‘Basal ganglia abnormalities’; 2, ‘Mesencephalon and/or brainstem abnormalities’; 3, ‘Atrophy’; 4, ‘Thalamus abnormalities’; and
5, ‘a combination of the abnormalities mentioned’ (1-4), PDHC= pyruvate dehydrogenase complex abnormalities
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Appendix 2
Table 5 Unlikely group characteristics





















(n = 2) (n = 25) (n = 8)
1. 2.2 Female Developmental delay of unknown origin - - 2.5 ND 1 ND 6 15
2. 0.8 Male Failure to thrive, rickets - - 1.2 ND 0 ND 6 14
3. 8.2 Male Developmental delay of unknown origin - - 0.9 ND 0 ND 7 15
4. 1.7 Female Developmental delay of unknown origin - - 3.6 ND 0 ND 8 21
5. 9.3 Female Raynaud’s phenomenon of unknown origin - - 0.6 1.9 0 60.8 7 20
6. 0.2 Male Exercise intolerance of unknown origin - - 3.5 1.5 0 ND 12 26
7. 12.2 Male Loss of skills - - 0.9 ND 0 ND 10 18
8. 3.2 Male Developmental delay of unknown origin - - 0.8 ND 0 ND 8 19
9. 6.2 Male Developmental delay of unknown origin - - 0.8 1.5 0 ND 10 19
10. 12.9 Male Mild retardation, autism - - 2.0 1.5 0 ND 10 19
11. 2.0 Male Developmental delay of unknown origin - - 1.0 ND 0 ND 7 17
12. 10.0 Male Severe retardation and autism - - 1.4 1.8 0 ND 9 13
13. 2.9 Male Bilateral movement disorder of unknown
origin
- - 3.3 ND 0 ND 11 20
14 0.5 Female Cryptogenic epilepsy, perceptive hearing loss - - 1.2 1.7 0 ND 11 19
15 5.1 Male Epilepsy, microcephaly 15q13.2q13.3
duplication
- 0.8 1.4 0 ND 8 11
16 4.7 Female Epilepsia partialis continua - - 1.5 1.5 0 ND 0 0
17. 0.1 Female Hypochondroplasia FGFR3-gen
mutation
- 1.7 1.2 0 ND 11 17
c.1620C >A,
p.Asn540Lys
18. 1.6 Male Developmental delay of unknown origin,
epilepsy
- - 1.4 1.5 0 ND 9 17
19 1.8 Female Psychomotor retardation, epilepsy 2q16.3 deletion - 0.7 ND 0 ND 9 18
20 3.4 Male Cockayne syndrome homozygous
mutation ercc8
- 0.7 2.2 0 55.2 9 23
21. 0.8 Male Suspected of Freeman-Sheldon syndrome - 3.6 1.2 2.0 1 ND 10 13
22 2.8 Male Epilepsy - - 1.5 1.5 0 ND 7 15
23. 1.1 Male Psychomotor retardation ARX mutation epilepsy - 1.2 1.4 0 ND 8 17
24. 1.8 Male Failure to thrive - - 2.5 ND 0 ND 8 20
25. 2.2 Male Motor development delay, perceptive hearing
loss of unknown origin
- - 1.7 1.6 0 ND 5 17
26 4.0 Male Developmental delay, PDD-NOS del(15)(q11.2),
del(10)(q26.3)
- 1.3 ND 0 ND 8 21
27 8.0 Female Falling of unknown origin - - 2.4 ND 0 ND 8 20
28 11.7 Male Motor retardation - - 0.5 ND 0 ND 7 14
29 5.4 Female Low IQ of unknown origin - - 1.5 1.3 0 ND 7 11
30 6.3 Male Epilepsy, developmental delay - - 1.3 1.4 0 ND 10 21
31. 10.0 Male Retardation, ADHD - - 0.5 ND 0 ND 8 16
32. 15.2 Male Developmental delay of unknown origin - - 2.8 ND 0 ND 12 16
33 4.6 Female Psychomotor retardation, hairy elbow
syndrome
- - 1.1 ND 0 ND 6 17
34 0.4 Female Tonus regulation disorder - - 1.1 1.6 0 ND 10 20
35. 2.7 Female Febrile seizure - - 1.3 1.6 0 ND 8 19
36 0.2 Male PROMwith lung hypoplasia, failure to thrive,
Peripheral pulmonary
- - 1.0 ND 0 ND 7 23
37. 5.7 Male Myotonia, slow motor development, exercise
intolerance
- - 2.7 1.0 0 51 10 21
38 2.5 Male Seizures of unknown origin - - 3.5 1.4 0 ND 8 16
39. 4.5 Male Retardation of unknown origin - - 0.6 ND 0 ND 7 15
40. 3.7 Male Muscle weakness of unknown origin - - 1.5 1.4 0 ND 8 17
41. 1.4 Male Atypical febrile seizures - - 0.6 1.6 0 ND 9 18
42. 13.8 Male Exercise intolerance - - 0.8 ND 0 ND 7 17
43. 3.3 Female Developmental delay, epilepsy of unknown
origin
- - 1.2 1.4 0 ND 8 16
44 0.1 Female Congenital cardio-myopathy - 0.1 2.4 1.6 0 22.4 8 18
a age at first MRS scan; b MRS lactate/creatine ratio The MRS reference subgroup = the first 10 cases; ND not determined; PDD-NOS pervasive
developmental disorder not otherwise specified; ADHD Attention Deficit Hyperactivity Disorder; PROM premature rupture of membranes; MRI
abnormality score: 0, ‘Normal’ (no abnormalities); 1, ‘Basal ganglia abnormalities’; 2, ‘Mesencephalon and/or brainstem abnormalities’; 3,
‘Atrophy’; 4, ‘Thalamus abnormalities’; and 5, ‘A combination of the abnormalities mentioned’ (1-4)
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